Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-13

Clinical Trial Update: "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

View source ↗

Summary

A retrospective study analyzed clinical factors associated with a high benefit of axitinib in metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Axitinib (Axitinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Status: COMPLETED | Results posted: 2020-03-13